Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REGIRI: Regorafenib + Irinotecan in Metastatic Gastro-oesophageal Adenocarcinomas
NCT03722108Phase 2Terminated
- Sponsor
- Unicancer
- Start
- Feb 2019
- Primary completion
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of regorafenib in gastroesophageal adenocarcinoma (2 arms), sponsored by Unicancer. Primary endpoint: Overall Survival at 10 months. Started Feb 2019; status: terminated.
02
Drugs
regorafenib
03
Conditions
gastroesophageal adenocarcinoma
Beyond the preview
Go deeper on NCT03722108.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03722108.